BMJ chief calls for a cure for medical 'mess'

June 24, 2010

The evidence base for clinical medicine and health policy is "a mess", with major problems affecting journals, regulation and public access to information.

Such were the views of Fiona Godlee, editor-in-chief of the British Medical Journal, who this week delivered the Sense About Science annual lecture.

Research into reporting bias, said Dr Godlee, had found "a major problem affecting the whole of medicine", with effects of intervention overstated and risks understated. Few positive studies remain unpublished, yet it is rare to find a paper reaching a negative conclusion about a drug, she claimed.

At the time of the recent flu "pandemic", some of the guidance offered by the World Health Organisation was written by people with links to industry, and even the term "pandemic" was redefined and diluted to trigger earlier interventions by government.

Such occurrences, Dr Godlee said, illustrated recurring themes. She cited "undisclosed conflicts of interest, pressures on academics, and industry-funded ghost- and guest-writers", not to mention the "key opinion leaders" the pharmaceutical industry deliberately builds up to influence prescribing decisions.

Nor, said Dr Godlee, can we have total confidence in regulators who are "largely industry-funded but don't declare conflicts of interest".

When it came to journals, she said, peer review is "slow, expensive, biased and unaccountable. It stifles innovation and is bad at detecting errors."

Sketching out "a more radical future", Dr Godlee said pharmaceutical companies could contribute to a fund for independent research. She urged a return to investigative journalism, and perhaps a medical version of the magazine Private Eye.

But she also said that many drugs were highly effective in relieving suffering while producing harmful side effects in a tiny proportion of cases. Perhaps, Dr Godlee suggested, it is time for greater honesty and "a more mature acceptance that no drugs are entirely safe", which could lead to "a new implicit contract" between drugs companies, regulators and the public.

You've reached your article limit

Register to continue

Registration is free and only takes a moment. Once registered you can read a total of 3 articles each month, plus:

  • Sign up for the editor's highlights
  • Receive World University Rankings news first
  • Get job alerts, shortlist jobs and save job searches
  • Participate in reader discussions and post comments

Have your say

Log in or register to post comments

Most Commented

Laurel and Hardy sawing a plank of wood

Working with other academics can be tricky so follow some key rules, say Kevin O'Gorman and Robert MacIntosh

Lady Margaret Hall, Oxford will host a homeopathy conference next month

Charity says Lady Margaret Hall, Oxford is ‘naive’ to hire out its premises for event

women leapfrog. Vintage

Robert MacIntosh and Kevin O’Gorman offer advice on climbing the career ladder

Woman pulling blind down over an eye
Liz Morrish reflects on why she chose to tackle the failings of the neoliberal academy from the outside
White cliffs of Dover

From Australia to Singapore, David Matthews and John Elmes weigh the pros and cons of likely destinations